Shouldn't the CDC be more circumspect before recommending this drug to millions of healthy infants on the basis of a few short-term studies of a couple thousand children? Do we know its effect on total mortality? Could there be a substantial major adverse event rate that small studies would miss? Could the drug affect the infants' immune system in other ways making children more susceptible to other infections? Will the manufacturer be required to do large, unbiased, post-market surveillance studies to assess RW effectiveness and safety? Also, you call the product a "drug" while the CDC Director called it an "immunization". I agree that it is a drug - a prophylactic monoclonal antibody therapy. CDC playing games with words will not promote public confidence.